Grade Iii Astrocytoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: GRD007 MIFTS: 61	Grade Iii Astrocytoma Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Grade Iii Astrocytoma

MalaCards integrated aliases for Grade Iii Astrocytoma:

Name: Grade Iii Astrocytoma ¹² ⁵³ ¹⁵

Anaplastic Astrocytoma ¹² ⁵³ ⁵⁹ ⁵⁵ ¹⁵ ⁷³

Grade Iii Astrocytic Tumor ¹²

Astrocytoma, Anaplastic ⁶

Characteristics:

Orphanet epidemiological data:

⁵⁹

anaplastic astrocytoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of eye, brain and other parts of central nervous system

Malignant neoplasm of brain

Malignant neoplasm: Brain, unspecified

Orphanet: ⁵⁹

Rare neurological diseases

External Ids:

Disease Ontology ¹² DOID:3078

MeSH ⁴⁴ D001254

NCIt ⁵⁰ C129292 C9477

SNOMED-CT ⁶⁸ 55353007

Orphanet ⁵⁹ ORPHA251589

UMLS via Orphanet ⁷⁴ C0334579

ICD10 via Orphanet ³⁴ C71.9

UMLS ⁷³ C0334579

Sources

Summaries for Grade Iii Astrocytoma

NIH Rare Diseases : ⁵³ Anaplastic astrocytoma is a rare, cancerous (malignant) type of brain tumor that arises from star-shaped brain cells called astrocytes. These cells surround and protect nerve cells in the brain and spinal cord. An anaplastic astrocytoma usually develops slowly over time, but may develop rapidly. Signs and symptoms vary depending on the location and size of the tumor and may include headaches, drowsiness, vomiting, and changes in personality or mental status. Some affected people have seizures, vision problems, weakness of the limbs, and/or coordination problems. Anaplastic astroctyomas usually occur sporadically but can be associated with a few rare, genetic disorders. Treatment may include surgery, radiation, and/or chemotherapy.

MalaCards based summary : Grade Iii Astrocytoma, also known as anaplastic astrocytoma, is related to glioma susceptibility 1 and oligoastrocytoma, and has symptoms including seizures, headache and motor manifestations. An important gene associated with Grade Iii Astrocytoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Temodar and Carmustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are Decreased viability in esophageal squamous lineage and Reduced mammosphere formation

Disease Ontology : ¹² An astrocytoma that is characterized by cells with regular, round to oval nuclei.

Sources

Related Diseases for Grade Iii Astrocytoma

Diseases related to Grade Iii Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 240)

#	Related Disease	Score	Top Affiliating Genes
1	glioma susceptibility 1	31.3	GFAP IDH2 TP53
2	oligoastrocytoma	30.4	GFAP IDH2 MGMT
3	pleomorphic xanthoastrocytoma	30.2	GFAP MGMT TP53
4	glioblastoma multiforme	30.1	CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
5	glioblastoma	30.1	CDK4 CDKN2A CDKN2B DMBT1 EGFR IDH2
6	fibrillary astrocytoma	30.0	GFAP IDH2 MGMT PCNA TP53
7	anaplastic oligodendroglioma	29.9	CDKN2A EGFR GFAP IDH2 MGMT
8	arteriovenous malformation	29.9	MMP9 PTEN VEGFA
9	renal cell carcinoma, nonpapillary	29.8	EGFR MMP2 MMP9 VEGFA
10	gliosarcoma	29.7	CDK4 EGFR GFAP MGMT MMP2 MMP9
11	medulloblastoma	29.7	CDK4 CDKN2B DMBT1 EGFR GFAP MGMT
12	glioma	29.3	CDK4 CDKN2A DMBT1 EGFR IDH2 MDM2
13	colorectal cancer	28.8	CDK4 CDKN2A EGFR MDM2 MGMT MMP2
14	oligodendroglioma	28.4	CDKN2A CDKN2B EGFR GFAP IDH2 MGMT
15	cellular ependymoma	10.3	GFAP TP53
16	cerebral convexity meningioma	10.3	GFAP TP53
17	bladder squamous cell carcinoma	10.3	CDKN2A TP53
18	bizarre leiomyoma	10.3	CDKN2A PCNA
19	actinic cheilitis	10.3	MDM2 TP53
20	malignant peritoneal mesothelioma	10.3	CDKN2A EGFR
21	undifferentiated embryonal sarcoma of the liver	10.3	CDK4 MDM2
22	preretinal fibrosis	10.3	GFAP VEGFA
23	frontal convexity meningioma	10.3	GFAP TP53
24	brain ependymoma	10.3	EGFR TP53
25	gliofibroma	10.3	GFAP TP53
26	zika virus infection	10.3	MDM2 TP53
27	protoplasmic astrocytoma	10.3	GFAP IDH2 TP53
28	oral leukoplakia	10.2	CDKN2A PCNA TP53
29	astrocytoma	10.2
30	suppressor of tumorigenicity 3	10.2	CDKN2A PCNA TP53
31	gemistocytic astrocytoma	10.2	GFAP IDH2 PTEN
32	intestinal disease	10.2	EGFR TP53 VEGFA
33	male reproductive system disease	10.2	PTEN TP53 VEGFA
34	ependymoma	10.2	EGFR GFAP MGMT
35	basaloid squamous cell carcinoma	10.2	CDKN2A EGFR TP53
36	ring chromosome 7	10.2	CDK4 MDM2 TP53
37	inverted papilloma	10.2	CDKN2A PCNA TP53
38	necrotizing sialometaplasia	10.2	CDKN2A GFAP TP53
39	acute lymphocytic leukemia	10.2	CDKN2A CDKN2B TP53
40	pre-malignant neoplasm	10.2	CDKN2A EGFR TP53
41	vulva cancer	10.2	CDKN2A EGFR TP53
42	gastric lymphoma	10.2	PCNA TP53 VEGFA
43	oropharynx cancer	10.2	CDKN2A EGFR TP53
44	juvenile pilocytic astrocytoma	10.2	CDKN2A GFAP TP53
45	verrucous carcinoma	10.2	CDKN2A MDM2 TP53
46	penile cancer	10.2	CDKN2A EGFR TP53
47	central nervous system lymphoma	10.2	CDKN2A MGMT TP53
48	in situ carcinoma	10.2	CDKN2A EGFR TP53
49	periosteal osteogenic sarcoma	10.2	CDK4 MDM2 TP53
50	anaplastic ependymoma	10.2	GFAP MDM2 PTEN

Graphical network of the top 20 diseases related to Grade Iii Astrocytoma:

Sources

Symptoms & Phenotypes for Grade Iii Astrocytoma

UMLS symptoms related to Grade Iii Astrocytoma:

seizures, headache, motor manifestations, sensory manifestations

GenomeRNAi Phenotypes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability in esophageal squamous lineage	GR00235-A	9.7	APOD BSG CDKN2A DMBT1 GFAP IDH2
2	Reduced mammosphere formation	GR00396-S	9.17	CDK4 EGFR IDH2 MDM2 MMP2 PCNA

MGI Mouse Phenotypes related to Grade Iii Astrocytoma:

⁴⁶ (show all 25)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	mortality/aging	MP:0010768	10.49	APOD BSG CDK4 CDKN2A CDKN2B DMBT1
2	growth/size/body region	MP:0005378	10.46	BSG CDK4 CDKN2A EGFR GFAP MDM2
3	homeostasis/metabolism	MP:0005376	10.44	APOD CDK4 CDKN2A CDKN2B DMBT1 EGFR
4	cardiovascular system	MP:0005385	10.43	APOD CDK4 CDKN2A EGFR GFAP IDH2
5	immune system	MP:0005387	10.43	BSG CDK4 CDKN2A CDKN2B DMBT1 EGFR
6	cellular	MP:0005384	10.42	CDK4 CDKN2A CDKN2B DMBT1 EGFR GFAP
7	behavior/neurological	MP:0005386	10.4	APOD CDK4 CDKN2A GFAP MDM2 MMP9
8	hematopoietic system	MP:0005397	10.39	BSG CDK4 CDKN2A CDKN2B EGFR MDM2
9	endocrine/exocrine gland	MP:0005379	10.37	BSG CDK4 CDKN2A CDKN2B EGFR MDM2
10	digestive/alimentary	MP:0005381	10.35	CDK4 CDKN2A DMBT1 EGFR GFAP MDM2
11	neoplasm	MP:0002006	10.35	CDK4 CDKN2A CDKN2B DMBT1 EGFR IDH2
12	nervous system	MP:0003631	10.3	APOD CDK4 CDKN2A EGFR GFAP MDM2
13	integument	MP:0010771	10.29	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP9
14	muscle	MP:0005369	10.27	CDK4 CDKN2A EGFR GFAP MDM2 MMP2
15	embryo	MP:0005380	10.25	CDK4 CDKN2A DMBT1 EGFR MDM2 PDGFRA
16	liver/biliary system	MP:0005370	10.13	BSG CDK4 CDKN2A EGFR MDM2 PTEN
17	no phenotypic analysis	MP:0003012	10.13	CDKN2A CDKN2B EGFR MDM2 MGMT OLIG2
18	limbs/digits/tail	MP:0005371	10.08	EGFR MDM2 MMP9 PDGFRA PTEN TP53
19	normal	MP:0002873	10.06	CDK4 EGFR GFAP MDM2 MMP2 PDGFRA
20	reproductive system	MP:0005389	10.03	BSG CDK4 CDKN2A CDKN2B EGFR MDM2
21	renal/urinary system	MP:0005367	10.02	CDK4 CDKN2B DMBT1 EGFR MDM2 MMP9
22	pigmentation	MP:0001186	9.91	CDK4 CDKN2A EGFR MDM2 PDGFRA PTEN
23	respiratory system	MP:0005388	9.9	BSG CDKN2A EGFR MGMT MMP2 MMP9
24	skeleton	MP:0005390	9.65	CDKN2A EGFR MDM2 MMP2 MMP9 OLIG2
25	vision/eye	MP:0005391	9.32	CDK4 CDKN2A EGFR GFAP MMP2 MMP9

Sources

Drugs & Therapeutics for Grade Iii Astrocytoma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Temodar ¹⁸ ⁴⁹	TEMOZOLOMIDE	Schering-Plough	August 1999
FDA Label: Temodar Disease/s that Drug Treats:refractory anaplastic astrocytoma Indications and Usage: ¹⁸ TEMODAR is an alkylating drug indicated for the treatment of adultpatients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantlywith radiotherapy and then as maintenance treatment. (1.1) Refractory anaplastic astrocytoma patients who have experienceddisease progression on a drug regimen containing nitrosoureaand procarbazine. (1.2) DrugBank Targets: ¹⁶ 1. DNA Mechanism of Action: ¹⁸ Target: DNA Action: alkylizer FDA: Temozolomide is not directly active but undergoes rapid nonenzymatic conversion at physiologic pH to the reactive compound5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide (MTIC). The cytotoxicity of MTIC is thought to be primarily due to alkylation ofDNA. Alkylation (methylation) occurs mainly at the O6 and N7 positions of guanine.

Drugs for Grade Iii Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 372)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carmustine

Approved, Investigational

Phase 3,Phase 1,Phase 2,Not Applicable

154-93-8

2578

Procarbazine

Approved, Investigational

Phase 3,Phase 2,Phase 1

671-16-9

4915

Lomustine

Approved, Investigational

Phase 3,Phase 2,Phase 1

13010-47-4

3950

Trioxsalen

Approved

Phase 3,Phase 2,Phase 1

3902-71-4

5585

Temozolomide

Approved, Investigational

Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

85622-93-1

5394

Dacarbazine

Approved, Investigational

Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

4342-03-4

5351166

Bevacizumab

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

216974-75-3

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Cobalt

Approved, Experimental

Phase 3

7440-48-4

104729

Vincristine

Approved, Investigational

Phase 3,Phase 2,Phase 1

57-22-7, 2068-78-2

5978

Vorinostat

Approved, Investigational

Phase 2, Phase 3,Phase 1

149647-78-9

5311

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Donepezil

Approved

Phase 3,Phase 2

120014-06-4

3152

Valproic Acid

Approved, Investigational

Phase 3,Phase 1,Phase 2

99-66-1

3121

tannic acid

Approved

Phase 3,Phase 2,Not Applicable

Benzocaine

Approved, Investigational

Phase 3,Phase 2,Not Applicable

94-09-7, 1994-09-7

2337

Fluorouracil

Approved

Phase 2, Phase 3,Phase 1

51-21-8

3385

Flucytosine

Approved, Investigational

Phase 2, Phase 3,Phase 1

2022-85-7

3366

chloroquine

Approved, Investigational, Vet_approved

Phase 3

54-05-7

2719

Dopamine

Approved

Phase 3,Phase 2,Early Phase 1,Not Applicable

51-61-6, 62-31-7

681

Histamine

Approved, Investigational

Phase 3

51-45-6, 75614-87-8

774

Cyproheptadine

Approved

Phase 3

129-03-3

2913

Methylphenidate

Approved, Investigational

Phase 3

113-45-1

4158

Isotretinoin

Approved

Phase 3,Phase 1

4759-48-2

5538 5282379

Ornithine

Approved, Nutraceutical

Phase 3

3184-13-2, 70-26-8

6262

Tretinoin

Approved, Investigational, Nutraceutical

Phase 3,Phase 1

302-79-4

5538 444795

Semustine

Experimental, Investigational

Phase 3

13909-09-6

Mitolactol

Investigational

Phase 3

10318-26-0

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Dianhydrogalactitol

Investigational

Phase 3

23261-20-3

Alkylating Agents

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Antineoplastic Agents, Alkylating

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Dermatologic Agents

Phase 3,Phase 1,Phase 2,Not Applicable

Ether

Phase 3,Phase 2,Phase 1

Photosensitizing Agents

Phase 3,Phase 2,Phase 1

Dihematoporphyrin Ether

Phase 3,Phase 2,Phase 1

Immunologic Factors

Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable

Angiogenesis Modulating Agents

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

Angiogenesis Inhibitors

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

Central Nervous System Depressants

Phase 3,Phase 1,Phase 2

Antineoplastic Agents, Phytogenic

Phase 3,Phase 1,Phase 2

Antimitotic Agents

Phase 3,Phase 1,Phase 2

Anti-Infective Agents

Phase 3,Phase 2,Phase 1

Antirheumatic Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Pharmaceutical Solutions

Phase 3,Phase 2,Phase 1

Antifungal Agents

Phase 2, Phase 3,Phase 1

Keratolytic Agents

Phase 3,Phase 1,Phase 2

Histone Deacetylase Inhibitors

Phase 2, Phase 3,Phase 1

Antibodies

Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 381)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma	Unknown status	NCT01656980	Phase 3	Carmustine
2	Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas	Unknown status	NCT00003788	Phase 3	carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
3	Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas	Completed	NCT00004259	Phase 3	BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
4	Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)	Completed	NCT00335075	Phase 3	Temozolomide;Semustine
5	Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly	Completed	NCT01502241	Phase 3	Temozolomide
6	Radiation Therapy in Treating Patients With Brain Cancer	Completed	NCT00002620	Phase 3	carmustine;chemotherapy;mitolactol
7	Radiotherapy for Malignant Astrocytomas in the Elderly	Completed	NCT00430911	Phase 3	Radiotherapy
8	Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide	Completed	NCT00717210	Phase 3	Temozolomide
9	Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma	Completed	NCT00003916	Phase 3
10	Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma	Completed	NCT01236560	Phase 2, Phase 3	Temozolomide;Vorinostat
11	High Light and Low Light Dose PDT in Glioma	Completed	NCT00118222	Phase 3	porfimer sodium
12	Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma	Completed	NCT00052455	Phase 3	lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
13	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
14	Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors	Completed	NCT00369785	Phase 3	donepezil hydrochloride;Placebo
15	Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients	Recruiting	NCT02796261	Phase 3	Eflornithine;Lomustine;Lomustine
16	Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma	Recruiting	NCT03633552	Phase 3	Temozolomide
17	International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)	Recruiting	NCT03243461	Phase 3	Temozolomide + Valproic Acid;Temozolomide + Chloroquine
18	A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas	Recruiting	NCT02629757	Phase 3	β-elemene
19	A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas	Recruiting	NCT01765088	Phase 3	Temozolomide;α-IFN
20	Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma	Recruiting	NCT00887146	Phase 3	concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
21	The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma	Active, not recruiting	NCT02414165	Phase 2, Phase 3	Toca FC;Lomustine;Temozolomide
22	Phase III Trial of Anaplastic Glioma Without 1p/19q LOH	Active, not recruiting	NCT00626990	Phase 3	temozolomide
23	VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM	Active, not recruiting	NCT03149575	Phase 3	VAL-083, Dianhydrogalactitol;Physician's Choice of Salvage Therapy - temozolomide;Physician's Choice of Salvage Therapy - lomustine;Physician's Choice of Salvage Therapy - carboplatin
24	Temozolomide Combine With Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost for Non Small Cell Lung Cancer Brain Metastases	Not yet recruiting	NCT03732482	Phase 2, Phase 3	Temozolomide capsules
25	Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma	Terminated	NCT00761280	Phase 3	trabedersen;temozolomide;carmustine;lomustine
26	Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer	Terminated	NCT01132547	Phase 3	cyproheptadine hydrochloride
27	Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors	Terminated	NCT00031798	Phase 3	methylphenidate hydrochloride
28	Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas	Withdrawn	NCT00003564	Phase 3	Isotretinoin;Procarbazine Hydrochloride
29	Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas	Unknown status	NCT01721577	Phase 1, Phase 2	AXL1717
30	Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas	Unknown status	NCT02238496	Phase 2	Perifosine;Temsirolimus
31	Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma	Unknown status	NCT00004204	Phase 2	temozolomide
32	Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas	Unknown status	NCT00492687	Phase 2	carboplatin;tamoxifen citrate;temozolomide
33	131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma	Unknown status	NCT00114309	Phase 2	131-I-TM-601;131I-TM601
34	A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain	Unknown status	NCT01403311	Phase 2	5-Aminolevuline Acid
35	Bevacizumab in Recurrent Grade II and III Glioma	Unknown status	NCT01164189	Phase 2	Temozolomide
36	Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm	Unknown status	NCT00009854	Phase 1, Phase 2	carmustine in ethanol
37	Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma	Completed	NCT00003470	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
38	Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma	Completed	NCT00003537	Phase 2	Antineoplaston therapy (Atengenal + Astugenal)
39	Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma	Completed	NCT00301418	Phase 1, Phase 2	Erlotinib
40	A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma	Completed	NCT00606008	Phase 2	Sunitinib Malate
41	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Anaplastic Astrocytoma	Completed	NCT00003621	Phase 2	carmustine;cisplatin;etoposide
42	Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse	Completed	NCT00003775	Phase 2	leflunomide
43	SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)	Completed	NCT00783393	Phase 2	Temozolomide
44	BNCT to Treat Glioma That Has Progressed Following Radiotherapy	Completed	NCT00115440	Phase 1, Phase 2
45	Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma	Completed	NCT00004017	Phase 2
46	Combination Chemotherapy for Patients With Brain Cancer	Completed	NCT00002814	Phase 2	paclitaxel;topotecan hydrochloride
47	Phase IIa Safety and Light Dose-escalation Study in Patients With Primary or Recurrent/High-grade Glioma Using the Litx™ System to Confirm the Zone of Tumor Destruction During the Intraoperative Treatment of Glioma	Completed	NCT00409214	Phase 2	LS11 (talaporfin sodium)
48	A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas	Completed	NCT00921167	Phase 2	Bevacizumab/Irinotecan
49	Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma	Completed	NCT01663012	Phase 2	Etirinotecan pegol
50	Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02)	Completed	NCT00589875	Phase 2	Valacyclovir

Search NIH Clinical Center for Grade Iii Astrocytoma

Sources

Genetic Tests for Grade Iii Astrocytoma

Sources

Anatomical Context for Grade Iii Astrocytoma

MalaCards organs/tissues related to Grade Iii Astrocytoma:

⁴¹

Brain, Spinal Cord, T Cells, Bone, Endothelial, Myeloid, Breast

Sources

Publications for Grade Iii Astrocytoma

Articles related to Grade Iii Astrocytoma:

(show top 50) (show all 246)

#	Title	Authors	Year
1	Erratum: Whole-exome sequencing identifies germline mutation in <i>TP53</i> and <i>ATRX</i> in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. ( 29858379 )		2018
2	Anaplastic Astrocytoma in a Child With Coffin-Siris Syndrome and a Germline SMARCE1 Mutation: A Case Report. ( 30499906 )	Lin B...Upadhyaya SA	2018
3	Recurrence of spinal anaplastic astrocytoma in a cat after surgical treatment and long-term follow-up. ( 29065804 )	Tamura S...Uchida K	2018
4	Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. ( 29130549 )	Galuppini F...Gardiman MP	2018
5	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. ( 29497819 )	Louis DN...Wesseling P	2018
6	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. ( 29564591 )	Reinhardt A...Capper D	2018
7	Whole-exome sequencing identifies germline mutation in TP53 and ATRX in a child with genomically aberrant AT/RT and her mother with anaplastic astrocytoma. ( 29602769 )	Nordfors K...Granberg KJ	2018
8	Diffusely Infiltrating Cerebellar Anaplastic Astrocytoma Effectively Controlled with Bevacizumab: Case Report and Literature Review. ( 29704688 )	Kohzuki H...Matsumura A	2018
9	Two successful pregnancies following fertility preservation in a patient with anaplastic astrocytoma: a case report. ( 29739361 )	Peyser A...Hershlag A	2018
10	Anaplastic astrocytoma and pituitary macroadenoma within the same patient: A rare case of intracranial collision tumor. ( 29766961 )	Naik H...Guha A	2018
11	Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma. ( 29772361 )	Otani Y...Date I	2018
12	The prognostic improvement of add-on bevacizumab for progressive disease during concomitant temozolomide and radiation therapy in the patients with glioblastoma and anaplastic astrocytoma. ( 30035459 )	Yamaguchi S...Houkin K	2018
13	Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. ( 28870792 )	Clarke J....Omuro A.	2017
14	Benefit with adjuvant chemotherapy in anaplastic astrocytoma. ( 28801187 )	Schiff D.	2017
15	Crossed Aphasia in a Patient with Anaplastic Astrocytoma of the Non-Dominant Hemisphere. ( 29299104 )		2017
16	Anaplastic astrocytoma with aquaporin-4 positive in CSF: A case report. ( 29390462 )		2017
17	Retinal Metastases From Anaplastic Astrocytoma. ( 28864383 )		2017
18	The Mystery of Multiple Masses: A Case of Anaplastic Astrocytoma. ( 28775924 )		2017
19	Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813. ( 27994066 )	Chang S...Mehta M	2017
20	A Case of Therapy-Related Acute Myeloid Leukemia Associated with Adjuvant Temozolomide Chemotherapy for Anaplastic Astrocytoma. ( 28288919 )	Kosugi K...Tomita H	2017
21	Commentary on "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813". ( 28340188 )	Marucci G	2017
22	Anaplastic astrocytoma cells not detectable on autopsy following long-term temozolomide treatment: A case report. ( 28451406 )	Hirano H...Arita K	2017
23	Extracranial bone metastases from recurrent anaplastic astrocytoma on FDG PET/CT: A case report a care-compliant article. ( 28591062 )	Li ZG...Mu HY	2017
24	Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes. ( 28629398 )	Kantorov? E...Kur?a E	2017
25	Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. ( 28675067 )	Malmstr?m A...Nordic Clinical Brain Tumor Study Group (NCBTSG)	2017
26	Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma. ( 28978179 )	Wu J...Yang L	2017
27	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )	Patel D....Markert J.	2016
28	Distinctive Genetic Profile With IDH1, TP53, and MLH1 Mutations in a Radiation-Induced Anaplastic Astrocytoma. ( 26185030 )	Mascelli S....Raso A.	2016
29	Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )	Patel D.M....Markert J.M.	2016
30	Ollier disease with anaplastic astrocytoma: A review of the literature and a unique case. ( 27656320 )	Gajavelli S....Graber J.	2016
31	Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. ( 27864706 )		2016
32	Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison. ( 27334276 )	Adeberg S...Rieken S	2016
33	Network analysis of microRNAs, transcription factors, target genes and host genes in human anaplastic astrocytoma. ( 27347075 )	Xue L...Wang S	2016
34	Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy. ( 27401155 )	Shin JY...Diaz AZ	2016
35	Rapid increase in cystic volume of an anaplastic astrocytoma misdiagnosed as neurocysticercosis: A case report. ( 27698865 )	Li HJ...Feng DF	2016
36	Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities. ( 26360803 )	Watanabe Y...Kure S	2016
37	The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( 26729269 )	Strowd RE...Grossman SA	2016
38	Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients. ( 26924115 )	Padwal JA...Chen CC	2016
39	Anaplastic astrocytoma. ( 27230974 )	Grimm SA...Chamberlain MC	2016
40	Metachronous spinal metastases from supratentorial anaplastic astrocytoma. ( 25767596 )	Raheja A....Sharma B.S.	2015
41	An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma. ( 26337554 )	Stival A....Sardi I.	2015
42	Anaplastic astrocytoma mimicking herpes simplex encephalitis in 13-year old girl. ( 26272584 )	Talathi S....Gold M.	2015
43	Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma. ( 25793136 )	Barajas R.F....Cha S.	2015
44	Intramedullary spinal glioblastoma metastasis from anaplastic astrocytoma of cerebellum: A case report and review of the literature. ( 26396627 )	Kuo K.L....Liang P.I.	2015
45	Chronic Phase Intracranial Hemorrhage Caused by Ruptured Pseudoaneurysm Induced by Carmustine Wafer Implantation for Insulo-opercular Anaplastic Astrocytoma: A Case Report. ( 26423018 )		2015
46	Nuclear Localization Signal-Enhanced Polyurethane-Short Branch Polyethylenimine-Mediated Delivery of Let-7a Inhibited Cancer Stem-Like Properties by Targeting the 3'-UTR of HMGA2 in Anaplastic Astrocytoma. ( 24898358 )	Yang MY...Ma HI	2015
47	A model of a patient-derived IDH1 mutant anaplastic astrocytoma with alternative lengthening of telomeres. ( 25471051 )	Borodovsky A...Riggins GJ	2015
48	Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study. ( 25563816 )	Chamberlain MC	2015
49	Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. ( 25577400 )	Kazda T...Laack NN	2015
50	Imaging findings of anaplastic astrocytoma in a child with maple syrup urine disease: a case report. ( 26084772 )	Aw-Zoretic J...Ryan ME	2015

Sources

Genes for Grade Iii Astrocytoma

Genes related to Grade Iii Astrocytoma (1 elite genes):

(show all 20)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	TP53	Tumor Protein P53	Protein Coding	434.27	Pathogenic ⁶ DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9839169 1336544 8599254 (more) 8337939 20090216 19876867 7494604 11550308 11355303 10063271 8108140 11504770 12700122 7494603 12389885 10741908 9042164 16875495 1346255 11764090 10666371 9815715 9341929 7536455 8118823 1758878 11051241 9225141 9529927 9370234 8965097 8682593 7477776 8123492 1501894 17917588 15269478 19716156 17721049 17327574 11048299 1686725 16818615 15981097 15659871 10079373 9407934 9049884 9815964 7534015 8397797 19435942 19151620 15175080 11724349 11175638 9485008 9115587 8676433 7582239 7903434 1349850 1886708 9887356 9577364 8583240 15455376 8529218 16776982
2	IDH2	Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial	Protein Coding	31.11	DISEASES inferred ¹⁵
3	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	25.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9779706 17721049 15455376 (more) 7549044 17691113 14744281 16936459 18575733 17965865 19346643 1501894 16849758 18945611
4	EGFR	Epidermal Growth Factor Receptor	Protein Coding	24.69	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17679463 11504770 10029453 (more) 1314448 19127042 8814167 12700122 16618782 8057151 9260461 9677449 19512898 15163002 8965097 20331873 16030116 15913199 11138928 7815080 17907599 12939468 19716156 17327574 16133418 15943037 11048299 17189383 16364761 9407934 8476201 1776845 11431323 15290895 1320666 16008822 16776982 1311022 8583240
5	PTEN	Phosphatase And Tensin Homolog	Protein Coding	24.12	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	11504770 9690672 19657395 (more) 11355303 10560660 10702383 10096247 15679305 18836294 17504928 12700122 10666371 10433932 11054184
6	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	24	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	14756441 1806058 1668298 (more) 19663312 7609842 8526753 11554096 7518371 1652162 7684178 8082240 17998256
7	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	23.01	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20090216 12968803 19127042 (more) 8712938 9677449 1357920 10736069 7681617 7974802 8529218 8800324
8	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.94	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7987821 12700122 9000591 (more) 7582239 7534015 12173338 16614947 7497469 10666371 12185811
9	MDM2	MDM2 Proto-Oncogene	Protein Coding	22.16	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	12700122 12241107 7815080 (more) 9266437 8504413 16319692
10	CDK4	Cyclin Dependent Kinase 4	Protein Coding	21.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7987821 16319692 9161727
11	DMBT1	Deleted In Malignant Brain Tumors 1	Protein Coding	21.54	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	10433932 12168116
12	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	20.33	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9669344 8616870 10741908 (more) 12777082 15973775 11683943 12702589 18719373 11507079 17318973 15088099 15700836 15175080 16158178
13	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	20.05	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	9000591
14	MMP2	Matrix Metallopeptidase 2	Protein Coding	19.56	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	7630025 10896208 11517976 (more) 8521615 9708803 18795327
15	PDGFRA	Platelet Derived Growth Factor Receptor Alpha	Protein Coding	19.4	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	17189383 16319692 17327574 (more) 14730454
16	BSG	Basigin (Ok Blood Group)	Protein Coding	18.68	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	18795327
17	MMP9	Matrix Metallopeptidase 9	Protein Coding	18.03	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	8521611 19657395 10638966 (more) 10845554 9708803
18	APOD	Apolipoprotein D	Protein Coding	17.88	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	16055749 11895042
19	OLIG2	Oligodendrocyte Transcription Factor 2	Protein Coding	12.18	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵	14575240 14730454 17917751 (more) 17415208
20	OLIG1	Oligodendrocyte Transcription Factor 1	Protein Coding	8.1	Novoseek inferred ⁵⁵	14730454 14575240

Sources

Variations for Grade Iii Astrocytoma

ClinVar genetic disease variations for Grade Iii Astrocytoma:

⁶

#	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	ATRX	NM_000489.4(ATRX): c.5579A> G (p.Asn1860Ser)	single nucleotide variant	Benign	rs45439799	GRCh37	Chromosome X, 76856021: 76856021
2	ATRX	NM_000489.4(ATRX): c.5579A> G (p.Asn1860Ser)	single nucleotide variant	Benign	rs45439799	GRCh38	Chromosome X, 77600552: 77600552
3	TP53	NM_000546.5(TP53): c.733G> A (p.Gly245Ser)	single nucleotide variant	Pathogenic	rs28934575	GRCh37	Chromosome 17, 7577548: 7577548
4	TP53	NM_000546.5(TP53): c.733G> A (p.Gly245Ser)	single nucleotide variant	Pathogenic	rs28934575	GRCh38	Chromosome 17, 7674230: 7674230

Sources

Expression for Grade Iii Astrocytoma

Search GEO for disease gene expression data for Grade Iii Astrocytoma.

Sources

Pathways for Grade Iii Astrocytoma

Pathways related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 67)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.89	CDK4 CDKN2A CDKN2B EGFR GFAP MDM2
2	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.76	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
3	Cellular Senescence (REACTOME) ⁶⁶ Show member pathways Cellular responses to stress ⁶⁶ Cellular Senescence ⁶⁶ Senescence-Associated Secretory Phenotype (SASP) ⁶⁶	13.16	CDK4 CDKN2A CDKN2B MDM2 TP53 VEGFA
4	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	13.04	CDK4 EGFR MDM2 PDGFRA PTEN TP53
5	Human cytomegalovirus infection ³⁷ Show member pathways Hepatitis B ³⁷ Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	13.02	CDK4 CDKN2A EGFR MDM2 MMP9 PCNA
6	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.82	CDK4 CDKN2A CDKN2B EGFR PTEN TP53
7	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.77	CDK4 CDKN2A EGFR MDM2 MMP9 PCNA
8	Downstream signaling events of B Cell Receptor (BCR) ⁶⁶ Show member pathways Activation of RAS in B cells ⁶⁶ Signaling by the B Cell Receptor (BCR) ⁶⁶	12.75	EGFR MDM2 PDGFRA PTEN TP53
9	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ Parkinson's Disease Pathway ⁶⁴ SREBP Proteolysis ⁶⁴	12.73	CDK4 MDM2 MGMT PCNA TP53
10	Pathways in cancer ³⁷	12.72	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
11	Mitotic G1-G1/S phases ⁶⁶ Show member pathways G1 to S cell cycle control ¹ G1/S Transition ⁶⁶	12.62	CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
12	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ¹	12.58	EGFR MDM2 MMP2 MMP9 TP53
13	DNA Damage ⁴	12.56	CDK4 CDKN2A MDM2 MGMT PCNA TP53
14	Human T-cell leukemia virus 1 infection ³⁷	12.48	CDK4 CDKN2A CDKN2B PCNA PDGFRA TP53
15	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.46	EGFR MDM2 PDGFRA TP53
16	MicroRNAs in cancer ³⁷	12.45	CDKN2A EGFR MDM2 MMP9 PDGFRA PTEN
17	Cushing syndrome ³⁷ Show member pathways Melanogenesis ³⁷	12.44	CDK4 CDKN2A CDKN2B EGFR
18	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.44	CDK4 CDKN2A MDM2 PTEN TP53
19	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.41	MDM2 PCNA PTEN TP53
20	Cell cycle ¹ ³⁷	12.4	CDK4 CDKN2A CDKN2B MDM2 PCNA TP53
21	Cyclins and Cell Cycle Regulation ⁶⁴ Show member pathways Cell Cycle Control by BTG Proteins ⁶⁴ Cyclin D associated events in G1 ⁶⁶ G1 Phase ⁶⁶ G1-S Phase Transition ⁶⁴ Phosphorylation of proteins involved in G1/S transition by active Cyclin E-Cdk2 complexes ⁶⁶	12.37	CDK4 CDKN2A CDKN2B TP53
22	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.37	CDK4 CDKN2A CDKN2B EGFR MDM2 MMP2
23	Viral carcinogenesis ³⁷	12.35	CDK4 CDKN2A CDKN2B MDM2 TP53
24	Proteoglycans in cancer ³⁷	12.34	EGFR MDM2 MMP2 MMP9 TP53 VEGFA
25	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.28	CDK4 MDM2 PTEN TP53
26	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.26	CDK4 EGFR MDM2 PDGFRA PTEN TP53
27	Colorectal Cancer Metastasis ⁶⁴	12.24	EGFR MMP2 MMP9 TP53 VEGFA
28	Cellular senescence (KEGG) ³⁷	12.21	CDK4 CDKN2A CDKN2B MDM2 PTEN TP53
29	AKT Signaling Pathway ⁶⁷	12.18	CDK4 EGFR MDM2 PDGFRA PTEN TP53
30	Integrated Breast Cancer Pathway ¹	12.17	CDK4 EGFR MDM2 PTEN TP53 VEGFA
31	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.16	EGFR MDM2 MMP2 PTEN
32	Fluid shear stress and atherosclerosis ³⁷	12.14	MMP2 MMP9 TP53 VEGFA
33	FoxO signaling pathway ³⁷ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.13	CDKN2B EGFR MDM2 PTEN
34	SMAD Signaling Network ⁶⁴	12.12	CDKN2A MDM2 MMP2 TP53 VEGFA
35	Direct p53 effectors ¹	12.09	EGFR MDM2 MMP2 PCNA PTEN TP53
36	Spinal Cord Injury ¹	12.06	CDK4 EGFR GFAP MMP9 TP53
37	DNA Damage Response (only ATM dependent) ¹	12.04	CDKN2A MDM2 PTEN TP53
38	Interleukin-4 and 13 signaling ⁶⁶	12.04	MMP2 MMP9 TP53 VEGFA
39	Senescence and Autophagy in Cancer ¹	12	CDKN2A MDM2 PCNA PTEN TP53
40	Small cell lung cancer ³⁷	11.94	CDK4 CDKN2B PTEN TP53
41	Retinoblastoma (RB) in Cancer ¹	11.9	CDK4 MDM2 PCNA TP53
42	Androgen receptor signaling pathway ¹	11.87	EGFR MDM2 PTEN
43	Angiogenesis (CST) ⁴	11.86	MMP2 MMP9 PDGFRA
44	Neural Stem Cell Differentiation Pathways and Lineage-specific Markers ⁶⁵	11.83	GFAP OLIG1 OLIG2 PDGFRA VEGFA
45	Validated targets of C-MYC transcriptional activation ¹	11.82	CDK4 MMP9 TP53
46	Glioblastoma Multiforme ⁶⁴	11.8	CDK4 CDKN2A EGFR MDM2 MGMT PDGFRA
47	Platinum drug resistance ³⁷	11.77	CDKN2A MDM2 TP53
48	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.76	CDKN2A MDM2 TP53
49	Central carbon metabolism in cancer ³⁷	11.76	EGFR PDGFRA PTEN TP53
50	Transcription_P53 signaling pathway ²²	11.76	CDKN2A MDM2 MMP2 TP53 VEGFA

Sources

GO Terms for Grade Iii Astrocytoma

Biological processes related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

(show all 26)

#	Name	GO ID	Score	Top Affiliating Genes
1	viral process	GO:0016032	9.99	DMBT1 MDM2 PCNA PDGFRA TP53
2	positive regulation of gene expression	GO:0010628	9.97	CDKN2A MDM2 PTEN TP53 VEGFA
3	angiogenesis	GO:0001525	9.92	APOD MMP2 PTEN VEGFA
4	positive regulation of cell migration	GO:0030335	9.92	EGFR MMP9 PDGFRA VEGFA
5	positive regulation of cell proliferation	GO:0008284	9.91	CDK4 EGFR MDM2 PDGFRA PTEN VEGFA
6	positive regulation of apoptotic process	GO:0043065	9.89	CDK4 CDKN2A MMP9 PTEN TP53
7	extracellular matrix organization	GO:0030198	9.88	BSG GFAP MMP9 PDGFRA
8	response to drug	GO:0042493	9.85	APOD CDK4 MDM2 MGMT PTEN
9	epithelial cell differentiation	GO:0030855	9.79	DMBT1 PCNA VEGFA
10	extracellular matrix disassembly	GO:0022617	9.73	BSG MMP2 MMP9
11	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	9.72	MDM2 PCNA TP53
12	cellular response to amino acid stimulus	GO:0071230	9.71	EGFR MMP2 PDGFRA
13	positive regulation of fibroblast proliferation	GO:0048146	9.7	CDK4 EGFR PDGFRA
14	positive regulation of vascular smooth muscle cell proliferation	GO:1904707	9.69	MDM2 MMP2 MMP9
15	embryo implantation	GO:0007566	9.65	BSG MMP2 MMP9
16	replicative senescence	GO:0090399	9.63	CDKN2A TP53
17	amyloid fibril formation	GO:1990000	9.61	CDKN2A MDM2
18	positive regulation of production of miRNAs involved in gene silencing by miRNA	GO:1903800	9.6	EGFR TP53
19	cellular response to reactive oxygen species	GO:0034614	9.58	EGFR MMP9 PDGFRA
20	cellular response to hypoxia	GO:0071456	9.56	MDM2 PTEN TP53 VEGFA
21	negative regulation of apoptotic process	GO:0043066	9.56	EGFR MDM2 MGMT MMP9 PDGFRA PTEN
22	cellular response to actinomycin D	GO:0072717	9.37	MDM2 TP53
23	positive regulation of DNA repair	GO:0045739	9.33	EGFR MGMT PCNA
24	positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway	GO:0038091	9.32	PDGFRA VEGFA
25	obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle	GO:0031658	8.92	CDK4 CDKN2A CDKN2B PTEN
26	multicellular organism development	GO:0007275	10.11	DMBT1 EGFR OLIG1 OLIG2 PDGFRA TP53

Molecular functions related to Grade Iii Astrocytoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein kinase binding	GO:0019901	9.77	CDKN2A CDKN2B EGFR PTEN TP53
2	enzyme binding	GO:0019899	9.65	EGFR MDM2 PCNA PTEN TP53
3	identical protein binding	GO:0042802	9.56	EGFR GFAP MDM2 MMP9 PCNA PTEN
4	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	9.4	CDKN2A CDKN2B
5	disordered domain specific binding	GO:0097718	9.33	CDKN2A MDM2 TP53
6	platelet-derived growth factor receptor binding	GO:0005161	8.8	PDGFRA PTEN VEGFA
7	protein binding	GO:0005515	10.25	APOD BSG CDK4 CDKN2A CDKN2B DMBT1

Sources

Sources for Grade Iii Astrocytoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia